Navigation Links
Luminex Corporation Reports 3rd Quarter 2015 Results
Date:11/2/2015

AUSTIN, Texas, Nov. 2, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the third quarter ended September 30, 2015.  Financial and operating highlights for the quarter include the following:

  • Increased third quarter 2015 revenue by 7 percent to $60.6 million, over the third quarter of 2014.
  • Increased Q3 2015 system sales by 26 percent to $9.6 million over the third quarter of 2014.
  • Grew third quarter 2015 assay revenue by 12 percent to $24.6 million over results from the third quarter of 2014.
  • Decreased operating expenses as a percentage of revenue to 53 percent for the third quarter of 2015, a 7 point improvement from the third quarter of 2014. 
  • Improved operating profits for the quarter by 94% as a result of both increased revenues and significant expense control.
  • Delivered GAAP net income for the third quarter of $6.4 million, or $0.15 per diluted share. Non-GAAP net income for the third quarter was $9.3 million, or $0.22 per diluted share (see Non-GAAP reconciliation).
  • Cash and short and long-term investments at quarter's end totaled approximately $136 million, an increase of approximately $28 million compared with year-end 2014.
  • Raising 2015 revenue guidance range to between $235 million and $238 million from the prior range of between $232 million and $236 million.
  • In October, Luminex submitted a 510(k) pre-market submission to the FDA for the ARIES® Group B Streptococcus (GBS) Assay.  
  • "This was a record quarter for Luminex as the Company exceeded $60 million in revenue for the first time.  Our solid performance in the quarter reflects the merits of our balanced business model and the focus on appropriate resource allocation. This coupled with the hard work of our dedicated employees resulted in an operating profit of approximately $10 million, nearly double the amount reported for the same period last year," said Homi Shamir, President and Chief Executive Officer of Luminex. "We believe that the recent FDA clearance for our ARIES® system and ARIES® HSV 1 & 2 assay will prove to be an exciting milestone for the Company in the large, sample-to-answer molecular diagnostic market. We look forward to launching ARIES this week at the Association for Molecular Pathology meeting in our home town of Austin."REVENUE SUMMARY
    (in thousands, except percentages)Three Months EndedSeptember 30,Variance20152014($)(%)(unaudited)System sales

    $
    9,622
    $
    7,624
    $1,99826%Consumable sales

    10,94012,124(1,184)-10%Royalty revenue

    10,2499,6905596%Assay revenue

    24,63922,0562,58312%All other revenue

    5,1515,190(39)-1%$  60,601$  56,684$3,9177%Nine Months EndedSeptember 30,Variance20152014($)(%)(unaudited)System sales

    $  22,129$  22,328$  (199)-1%Consumable sales

    32,71437,521(4,807)-13%Royalty revenue

    32,02429,2152,80910%Assay revenue

    74,32363,60210,72117%All other revenue

    16,06916,211(142)-1%$177,259$168,877$8,3825%


    Additional Financial Highlights:

  • Infectious disease assay sales were approximately 68 percent of total assay sales for the quarter and genetic testing assays were 32 percent.
  • Royalty revenues reflect total royalty-bearing end-user sales for the quarter of $120.8 million.
  • 307 multiplexing analyzers were shipped during the quarter, which included 113 MAGPIX® systems, 164 LX systems, and 30 FLEXMAP 3D® systems.
  • Cash and investments at quarter-end totaled $135.6 million.
  • Days sales outstanding (DSO) was 40 days at quarter-end.
  • FINANCIAL OUTLOOK AND GUIDANCE

    The Company updates its revenue guidance range for the full-year 2015 to between $235 million and $238 million.

    CONFERENCE CALL

    Management will host a conference call at 3:30 p.m. CST/4:30 p.m. EST, Monday, November 2, 2015 to discuss the operating highlights and financial results for the third quarter ended September 30, 2015. The conference call will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; the development progress of our pipeline products, including ARIES and NxTAG products, market acceptance of our products, including instruments, consumables and assays, regulatory clearance of our products; the ability of our investment in current initiatives and new products to drive long-term value for our shareholders; and, projected 2015 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology in development, including ARIES and NxTAG, the uncertainty relating to increased focus on direct sales to the end user, dependence on strategic partners for development, commercialization and distribution of products, concentration of Luminex' revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex' technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges, the timing of and process for regulatory approvals, the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex' partners and end users and their ability to finance purchases of Luminex' products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of Luminex' assay products, Luminex' ability to obtain and enforce intellectual property protections on Luminex' products and technologies, risks and uncertainties associated with implementing Luminex' acquisition strategy, including Luminex' ability to obtain financing, Luminex' ability to integrate acquired companies or selected assets into Luminex' consolidated business operations, and the ability to recognize the benefits of Luminex' acquisitions, reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, changes in principal members of Luminex' management staff, potential shortages, or increases in costs, of components or other disruptions to Luminex' manufacturing operations, competition and competitive technologies utilized by Luminex' competitors, Luminex' ability to successfully launch new products in a timely manner, Luminex' increasing dependency on information technology to enable Luminex to improve the effectiveness of Luminex' operations and to monitor financial accuracy and efficiency, the implementation, including any modification, of Luminex' strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, and risks relating to Luminex' foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2015 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

     LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)September 30,December 31,20152014(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $
    9,553
    $
    91,694
    Short-term investments

    12,006-Accounts receivable, net

    26,16128,272Inventories, net

    29,31536,616Deferred income taxes

    5,12512,203Prepaids and other

    9,6948,235Total current assets

    201,854177,020Property and equipment, net

    48,03739,945Intangible assets, net

    53,92756,382Deferred income taxes

    15,12915,400Long-term investments

    4,00315,975Goodwill

    49,61949,619Other

    3,7583,185Total assets

    $
    376,327
    $
    357,526
    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $
    9,283
    $
    ,841
    Accrued liabilities

    13,00514,118Deferred revenue

    4,3734,407Total current liabilities

    26,66130,366Deferred revenue

    2,1192,297Other

    5,0414,869Total liabilities

    33,82137,532Stockholders' equity:Common stock

    4242Additional paid-in capital

    315,803309,424Accumulated other comprehensive loss

    (1,095)(744)Retained earnings

    27,75611,272Total stockholders' equity

    342,506319,994Total liabilities and stockholders' equity

    $
    376,327
    $
    357,526


     LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2015201420152014(unaudited)(unaudited)Revenue

    $60,601$56,684$177,259$168,877Cost of revenue

    18,78917,67451,95851,766Gross profit

    41,81239,010125,301117,111Operating expenses:Research and development

    10,09310,32731,74832,719Selling, general and administrative

    21,23621,42361,74061,838Amortization of acquired intangible assets

    7779642,4552,949Restructuring costs

    -1,300-1,653Total operating expenses

    32,10634,01495,94399,159Income from operations

    9,7064,99629,35817,952Interest expense from long-term debt

    ---(6)Other income, net

    13(15)964(35)Settlement of litigation

    --(7,300)-Income before income taxes

    9,7194,98123,02217,911Income tax expense

    (3,317)569(6,538)(1,670)Net income

    $  6,402$  5,550$  16,484$  16,241Net income per share, basic

    $
    .15
    $
    .13
    $
    .39
    $
    .39
    Shares used in computing net income per share, basic

    42,15241,71442,04141,496Net income per share, diluted

    $
    .15
    $
    .13
    $
    .39
    $
    .39
    Shares used in computing net income per share, diluted

    42,55642,38142,35442,127


    0

    GOOD


    Related medicine technology :

    1. Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
    2. Luminex Corporation and Bio-Techne Corporation Extend and Expand Partnership
    3. Luminex Corporation Third Quarter Earnings Release Scheduled for November 2, 2015
    4. Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference
    5. Luminex Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference
    6. Luminex Corporation Reports Record 2nd Quarter 2015 Results
    7. Luminex Corporation Second Quarter Earnings Release Scheduled for August 3, 2015
    8. Luminex Corporation Reports First Quarter 2015 Results
    9. Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R)
    10. Luminex Corporation First Quarter Earnings Release Scheduled for May 4, 2015
    11. Luminex Technology Selected by Assurex Health
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... The findings ... lung illness in the individuals studied could be caused by toxic chemicals rather than ... Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping): A Report of Eight Cases ,” ...
    (Date:10/15/2019)... (PRWEB) , ... October 14, ... ... VALIDATE® LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order ... and Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and ...
    (Date:10/15/2019)... ... ... Twiggy Bean, Ph.D., wanted to educate others about the divorce bullying epidemic ... and become truly child focused. This objective prompted her to write “Divorce Bullying: An ... Don’t be a divorce bully!” (published by Balboa Press), a guidebook that serves as ...
    Breaking Medicine Technology:
    (Date:10/11/2019)... ... 2019 , ... Inland Detox, Inc. has just moved to a new location ... of the Temecula Valley and it’s the perfect place for long-term residential alcohol ... rooms as well as double occupancy rooms, a 2nd home where all treatment takes ...
    (Date:10/10/2019)... ... October 10, 2019 , ... In attendance at this ... to hear the significant results of an independent study presented by researchers from ... clinical study poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine ...
    (Date:10/8/2019)... San Jose, CA (PRWEB) , ... October 08, 2019 , ... ... patients with gum disease in San Jose, CA experience relief from this common and ... as possible in order to save adults from living with uncomfortable symptoms, including tender ...
    (Date:10/8/2019)... ... , ... Over the past three decades, Buffalo Wings & Rings has elevated ... by providing a higher-quality product and experience than the competition. Now, the club-level sports ... A MUG FOR THE CAUSE" campaign in support of Breast Cancer Awareness Month. ...
    (Date:10/8/2019)... ... 08, 2019 , ... EBSCO Information Services ( EBSCO ) ... content from Dynamic Health™ into the MCN platform. Dynamic Health is ... skills. MCN provides custom policy content, document management software and compliance expertise to ...
    Breaking Medicine News(10 mins):